High-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience

Aim. To assess the long-term results of high-dose chemotherapy following autologous hematopoietic stem cell transplantation (autoHSCT) for multiple myeloma (MM) in the real setting and influence of different factors on the results. Materials and methods. From 2006 till 2018 in Pirogovs Center wer...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nikita E. Mochkin, Vladislav O. Sarzhevskiy, Julia N. Dubinina, Elena G. Smirnova, Denis A. Fedorenko, Anna E. Bannikova, Dina S. Kolesnikova, Vladimir S. Bogatyrev, Anastasia A. Samoylova, Nikolay M. Faddeev, Vladimir Ya. Melnichenko
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2020
Materias:	multiple myeloma high-dose chemotherapy autologous hematopoietic stem cell transplantation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/71812a52bfeb4a50a069644ca48f8b9e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:71812a52bfeb4a50a069644ca48f8b9e
record_format	dspace
spelling	oai:doaj.org-article:71812a52bfeb4a50a069644ca48f8b9e2021-11-30T17:03:34ZHigh-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience1815-14341815-144210.26442/18151434.2020.2.200179https://doaj.org/article/71812a52bfeb4a50a069644ca48f8b9e2020-07-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/35195/23618https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Aim. To assess the long-term results of high-dose chemotherapy following autologous hematopoietic stem cell transplantation (autoHSCT) for multiple myeloma (MM) in the real setting and influence of different factors on the results. Materials and methods. From 2006 till 2018 in Pirogovs Center were performed 205 autoHSCT for patients with MM, aged between 3172 years (median 55). 55 (26.8%) autoHSCT were tandem. The study population consisted of 45% men and 55% women. Median follow up was 75 months. For the majority of patients autoHSCT was performed after achieving at least partial response according to the IMWG criteria. For less than 9% patients, autoHSCT was done for chemo refractory disease as a salvage therapy. Most of the patients 179 (87.4%) were treated using melphalan-based conditioning regimens (140 or 200 mg/m2). Initial staging according to ISS was done for less than 30% and to R-ISS less than 5% patients. No transplant-related mortality till D + 100 was registered. 186 patients were included in the final analysis. Results. The 5-year OS and PFS were 73% and 34%, respectively, that corresponds with international data. For patients, younger than 60, 5-year OS was 82%; for patients older than 60, it was 49% (p0.05). For tandem autoHSCT, 5-year PFS was 44%; for single autoHSCT 26% (p0.05). 5-year PFS after autoHSCT was significantly higher in patients with complete and stringent complete response after autoHSCT (44%) in comparison with the group with partial and very good partial response (77%). Sex, response before and after autoHSCT, immunomodulatory drugs in induction, number of prior lines of induction therapy, conditioning regimen and maintenance therapy had no influence on OS. PFS had the same tendencies, except tumor response after autoHSCT. Conclusion. In a real setting, we recommend tandem autoHSCT for all eligible patients with chemosensitive disease, despite the depth of response and induction therapy. Patients younger than 60 and patients with complete of greater response after autoHSCT, benefit from the autoHSCT most. Implementation of total cytogenetic testing according to the R-ISS is of a great value for further development of autoHSCT for MM in Russia.Nikita E. MochkinVladislav O. SarzhevskiyJulia N. DubininaElena G. SmirnovaDenis A. FedorenkoAnna E. BannikovaDina S. KolesnikovaVladimir S. BogatyrevAnastasia A. SamoylovaNikolay M. FaddeevVladimir Ya. MelnichenkoIP Habib O.N.articlemultiple myelomahigh-dose chemotherapyautologous hematopoietic stem cell transplantationNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 2, Pp 126-132 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	multiple myeloma high-dose chemotherapy autologous hematopoietic stem cell transplantation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	multiple myeloma high-dose chemotherapy autologous hematopoietic stem cell transplantation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Nikita E. Mochkin Vladislav O. Sarzhevskiy Julia N. Dubinina Elena G. Smirnova Denis A. Fedorenko Anna E. Bannikova Dina S. Kolesnikova Vladimir S. Bogatyrev Anastasia A. Samoylova Nikolay M. Faddeev Vladimir Ya. Melnichenko High-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience
description	Aim. To assess the long-term results of high-dose chemotherapy following autologous hematopoietic stem cell transplantation (autoHSCT) for multiple myeloma (MM) in the real setting and influence of different factors on the results. Materials and methods. From 2006 till 2018 in Pirogovs Center were performed 205 autoHSCT for patients with MM, aged between 3172 years (median 55). 55 (26.8%) autoHSCT were tandem. The study population consisted of 45% men and 55% women. Median follow up was 75 months. For the majority of patients autoHSCT was performed after achieving at least partial response according to the IMWG criteria. For less than 9% patients, autoHSCT was done for chemo refractory disease as a salvage therapy. Most of the patients 179 (87.4%) were treated using melphalan-based conditioning regimens (140 or 200 mg/m2). Initial staging according to ISS was done for less than 30% and to R-ISS less than 5% patients. No transplant-related mortality till D + 100 was registered. 186 patients were included in the final analysis. Results. The 5-year OS and PFS were 73% and 34%, respectively, that corresponds with international data. For patients, younger than 60, 5-year OS was 82%; for patients older than 60, it was 49% (p0.05). For tandem autoHSCT, 5-year PFS was 44%; for single autoHSCT 26% (p0.05). 5-year PFS after autoHSCT was significantly higher in patients with complete and stringent complete response after autoHSCT (44%) in comparison with the group with partial and very good partial response (77%). Sex, response before and after autoHSCT, immunomodulatory drugs in induction, number of prior lines of induction therapy, conditioning regimen and maintenance therapy had no influence on OS. PFS had the same tendencies, except tumor response after autoHSCT. Conclusion. In a real setting, we recommend tandem autoHSCT for all eligible patients with chemosensitive disease, despite the depth of response and induction therapy. Patients younger than 60 and patients with complete of greater response after autoHSCT, benefit from the autoHSCT most. Implementation of total cytogenetic testing according to the R-ISS is of a great value for further development of autoHSCT for MM in Russia.
format	article
author	Nikita E. Mochkin Vladislav O. Sarzhevskiy Julia N. Dubinina Elena G. Smirnova Denis A. Fedorenko Anna E. Bannikova Dina S. Kolesnikova Vladimir S. Bogatyrev Anastasia A. Samoylova Nikolay M. Faddeev Vladimir Ya. Melnichenko
author_facet	Nikita E. Mochkin Vladislav O. Sarzhevskiy Julia N. Dubinina Elena G. Smirnova Denis A. Fedorenko Anna E. Bannikova Dina S. Kolesnikova Vladimir S. Bogatyrev Anastasia A. Samoylova Nikolay M. Faddeev Vladimir Ya. Melnichenko
author_sort	Nikita E. Mochkin
title	High-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience
title_short	High-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience
title_full	High-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience
title_fullStr	High-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience
title_full_unstemmed	High-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience
title_sort	high-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. single-center experience
publisher	IP Habib O.N.
publishDate	2020
url	https://doaj.org/article/71812a52bfeb4a50a069644ca48f8b9e
work_keys_str_mv	AT nikitaemochkin highdosechemotherapyfollowingautologoushematopoieticstemcelltransplantationformultiplemyelomaintherealworldsettingsinglecenterexperience AT vladislavosarzhevskiy highdosechemotherapyfollowingautologoushematopoieticstemcelltransplantationformultiplemyelomaintherealworldsettingsinglecenterexperience AT juliandubinina highdosechemotherapyfollowingautologoushematopoieticstemcelltransplantationformultiplemyelomaintherealworldsettingsinglecenterexperience AT elenagsmirnova highdosechemotherapyfollowingautologoushematopoieticstemcelltransplantationformultiplemyelomaintherealworldsettingsinglecenterexperience AT denisafedorenko highdosechemotherapyfollowingautologoushematopoieticstemcelltransplantationformultiplemyelomaintherealworldsettingsinglecenterexperience AT annaebannikova highdosechemotherapyfollowingautologoushematopoieticstemcelltransplantationformultiplemyelomaintherealworldsettingsinglecenterexperience AT dinaskolesnikova highdosechemotherapyfollowingautologoushematopoieticstemcelltransplantationformultiplemyelomaintherealworldsettingsinglecenterexperience AT vladimirsbogatyrev highdosechemotherapyfollowingautologoushematopoieticstemcelltransplantationformultiplemyelomaintherealworldsettingsinglecenterexperience AT anastasiaasamoylova highdosechemotherapyfollowingautologoushematopoieticstemcelltransplantationformultiplemyelomaintherealworldsettingsinglecenterexperience AT nikolaymfaddeev highdosechemotherapyfollowingautologoushematopoieticstemcelltransplantationformultiplemyelomaintherealworldsettingsinglecenterexperience AT vladimiryamelnichenko highdosechemotherapyfollowingautologoushematopoieticstemcelltransplantationformultiplemyelomaintherealworldsettingsinglecenterexperience
_version_	1718406386985992192

High-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience

Ejemplares similares